Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer

Bowel cancer cells in the colon

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth leading cause of cancer-related deaths. For patients, current therapy primarily entails surgical removal of the tumour and chemotherapy, to which tumours are variably responsive.

The immune system can be a double-edged sword in cancer because it can both combat and contribute to tumour development. The Powrie Group at the Kennedy Institute of Rheumatology were interested understanding the role of molecule IL-22, produced by immune cells, and to identify mechanisms by which it might influence CRC.

Their research published in Clinical Cancer Research found a link between the receptor for IL-22 and a mutation in the gene KRAS, showing that they work cooperatively to promote excessive growth and division of tumour cells. This is hypothesised to explain why prognosis is significantly worse for patients whose tumours have both a mutation in KRAS and high expression of the IL-22 receptor.

 

IL-22 is critical in maintaining immune homeostasis by triggering the release of anti-microbial substances and the healthy turnover of the cells that line the gut. Nonetheless, there is growing evidence that IL-22 can be detrimental by promoting excessive proliferation of tumour cells. We have shown this to be particularly true for cancer cells that have a mutation in the gene KRAS, which is present in 40-45% of colorectal tumours. - Beth Mann, Postdoc Researcher in Gut T Cell Regulation at the Kennedy Institute for Rheumatology, University of Oxford.

 

KRAS-mutant tumours are particularly poorly responsive to certain standard therapies and despite considerable efforts, the development of KRAS inhibitors has been largely unsuccessful. These latest results mean that for patients whose tumours have a KRAS mutation and high amounts of IL-22 receptor closer monitoring and more aggressive or alternative therapy strategies (like blocking IL-22) may be beneficial.

The research was primarily funded by an ‘Experimental Medicine Challenge Grant’ from the MRC and CRUK Grand Challenge funding (OPTIMISTICC).

See the original article on the NDORMS website here.

Similar Stories

Research confirms important differences in colorectal cancer patients with a history of Inflammatory Bowel Disease

IBD-associated colorectal cancers were found to occur in younger patients and have worse outcomes. Researchers call for urgent improvement of early detection methods to provide more risk-based and personalised care.

Nuffield Department of Medicine receives funding to improve bowel cancer treatment

The Leedham Lab in the Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.

Assessing a combined approach for risk-stratified population screening for colorectal cancer

Polygenic risk scores only modestly improve the predictive power of the QCancer-10 non-genetic risk score for colorectal cancer.